JP4691320B2 - Composition for inhibiting fat accumulation - Google Patents
Composition for inhibiting fat accumulation Download PDFInfo
- Publication number
- JP4691320B2 JP4691320B2 JP2003433948A JP2003433948A JP4691320B2 JP 4691320 B2 JP4691320 B2 JP 4691320B2 JP 2003433948 A JP2003433948 A JP 2003433948A JP 2003433948 A JP2003433948 A JP 2003433948A JP 4691320 B2 JP4691320 B2 JP 4691320B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- fat accumulation
- composition
- mass
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000009825 accumulation Methods 0.000 title claims description 43
- 239000000203 mixture Substances 0.000 title description 40
- 230000002401 inhibitory effect Effects 0.000 title description 30
- 239000003921 oil Substances 0.000 claims description 39
- 235000019198 oils Nutrition 0.000 claims description 38
- 239000000341 volatile oil Substances 0.000 claims description 37
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 9
- 235000011613 Pinus brutia Nutrition 0.000 claims description 9
- 241000018646 Pinus brutia Species 0.000 claims description 9
- 239000001524 citrus aurantium oil Substances 0.000 claims description 9
- 239000010643 fennel seed oil Substances 0.000 claims description 9
- 239000010648 geranium oil Substances 0.000 claims description 9
- 235000019717 geranium oil Nutrition 0.000 claims description 9
- 239000010651 grapefruit oil Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 244000147568 Laurus nobilis Species 0.000 claims description 8
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 8
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000001735 hyssopus officinalis l. herb oil Substances 0.000 claims description 8
- 239000010666 rose oil Substances 0.000 claims description 6
- 235000019719 rose oil Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000001902 eugenia caryophyllata l. bud oil Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003925 fat Substances 0.000 description 53
- 235000019197 fats Nutrition 0.000 description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- -1 nicotinic acid β-butoxyethyl ester Chemical class 0.000 description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 10
- 229960001948 caffeine Drugs 0.000 description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 239000010668 rosemary oil Substances 0.000 description 8
- 229940058206 rosemary oil Drugs 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 239000010628 chamomile oil Substances 0.000 description 7
- 235000019480 chamomile oil Nutrition 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000010633 clary sage oil Substances 0.000 description 6
- 239000010642 eucalyptus oil Substances 0.000 description 6
- 229940044949 eucalyptus oil Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 238000001256 steam distillation Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000011118 potassium hydroxide Nutrition 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229940074052 glyceryl isostearate Drugs 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 4
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- VPKMGDRERYMTJX-CMDGGOBGSA-N 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one Chemical compound CCC(=O)\C=C\C1C(C)=CCCC1(C)C VPKMGDRERYMTJX-CMDGGOBGSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 2
- 240000005020 Acaciella glauca Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 241000590810 Corades Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 244000061408 Eugenia caryophyllata Species 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 241000208181 Pelargonium Species 0.000 description 2
- 235000008582 Pinus sylvestris Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- 244000052585 Rosa centifolia Species 0.000 description 2
- 244000181025 Rosa gallica Species 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 235000002911 Salvia sclarea Nutrition 0.000 description 2
- 244000182022 Salvia sclarea Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 235000000484 citronellol Nutrition 0.000 description 2
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 2
- AFYCEAFSNDLKSX-UHFFFAOYSA-N coumarin 460 Chemical compound CC1=CC(=O)OC2=CC(N(CC)CC)=CC=C21 AFYCEAFSNDLKSX-UHFFFAOYSA-N 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 2
- 239000003915 liquefied petroleum gas Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000001839 pinus sylvestris Substances 0.000 description 2
- 239000001738 pogostemon cablin oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010671 sandalwood oil Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 235000019983 sodium metaphosphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IMMBLRJLSYJQIZ-UNQGIHKMSA-N (2S)-7-[3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one Chemical compound COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(OC4OC(CO)C(O)C(O)C4O)C(O)C3O)cc2O1 IMMBLRJLSYJQIZ-UNQGIHKMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RZRILSWMGXWSJY-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;sulfuric acid Chemical compound OS(O)(=O)=O.OCCN(CCO)CCO RZRILSWMGXWSJY-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241000017552 Alepisauridae Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 241000510609 Ferula Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000208150 Geraniaceae Species 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241001671311 Laurus Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 241000123826 Lutjanus campechanus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150118484 Macf1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- GUUHFMWKWLOQMM-UHFFFAOYSA-N alpha-n-hexylcinnamic aldehyde Natural products CCCCCCC(C=O)=CC1=CC=CC=C1 GUUHFMWKWLOQMM-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000011694 cabbage rose Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 description 1
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000001143 laurus nobilis l. Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Landscapes
- Artificial Filaments (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は脂肪蓄積抑制用組成物、特に精油を含む脂肪蓄積抑制用組成物に関する。 The present invention relates to a composition for inhibiting fat accumulation, and particularly to a composition for inhibiting fat accumulation comprising essential oil.
肥満は各種生活習慣病の温床であり、健康維持のためには肥満の改善が重要である。カロリー摂取過剰、運動不足の現代社会では肥満傾向にある人が多く、日本では肥満の基準とされるBMI(体格指数)25を超える人が男性で1300万人、女性で1000万人程度存在すると言われており、肥満改善方法を提供することが重要な課題となっている。肥満の原因は、摂取した過剰なカロリーが中性脂肪として脂肪組織(脂肪細胞)に蓄えられることにある。 Obesity is a hotbed for various lifestyle-related diseases, and improvement of obesity is important for maintaining health. There are many people who are obese in modern society with excessive caloric intake and lack of exercise. In Japan, there are about 13 million men and 10 million women who exceed BMI (physique index) 25, which is the standard for obesity. It is said that providing an obesity improvement method has become an important issue. The cause of obesity is that excessive calories ingested are stored in adipose tissue (adipocytes) as neutral fat.
痩身効果を有する薬剤を開発する目的で、脂肪合成の抑制や脂肪分解の促進等の効果を示す各種生薬、エキス類、薬剤等のスクリーニングが行なわれている。例えば、カフェインが過剰脂肪蓄積を軽減させること、トウガラシエタノール抽出物が分化成熟抑制によると思われる作用により脂肪中性脂肪量を減少させることがすでに報告されている。
一方、植物を水蒸気蒸留することで得られる精油は、殺菌作用、抗炎症作用、鎮静作用など、従来から伝承的、経験的に様々な薬理的作用が知られている。
On the other hand, essential oils obtained by steam-distilling plants have conventionally been known for various pharmacological actions such as bactericidal action, anti-inflammatory action, and sedative action.
しかしながら、脂肪蓄積抑制効果、肥満改善効果、特に脂肪組織(脂肪細胞)への直接作用を体系的に調べた研究例はほとんど報告されていない。
脂肪組織に作用して痩身や肥満予防効果を示す精油を探索し、これら効果を有する精油を配合した皮膚外用剤、衣料、食品等を提供することは、肥満を改善し人々の健康を維持する上で重要な課題であり、産業上の利用価値も大きい。
本発明は、前述のような課題に鑑み行なわれたものであり、その目的は、脂肪組織へ直接作用させることにより、脂肪の蓄積を抑制させることのできる脂肪蓄積抑制用組成物を提供することにある。
However, there have been few reports on researches that systematically investigated the effect of suppressing fat accumulation, the effect of improving obesity, particularly the direct action on adipose tissue (adipocytes).
Searching for essential oils that act on adipose tissue to prevent slimming and obesity, and providing skin preparations, clothing, foods, etc. that contain these essential oils improve obesity and maintain people's health It is an important issue above, and its industrial utility value is also great.
The present invention has been made in view of the above-described problems, and an object of the present invention is to provide a fat accumulation-suppressing composition capable of suppressing fat accumulation by directly acting on adipose tissue. It is in.
本発明者らは上記課題を解決すべく検討した結果、特定の精油は、脂肪組織に直接作用し、脂肪細胞内への脂肪の蓄積を抑制させる効果を有することを見出し、本発明を完成した。
すなわち、本発明の第一の主題は、ユーカリオイル、ローレルオイル、グレープフルーツオイル、ローズマリーオイル、クローブバッドオイル、カモミールオイル、ローズオイル、ゼラニウムオイル、ネロリオイル、パインニードルオイル、ヒソップオイル、フェンネルオイル、クラリセージオイル、及びガルバナムオイルからなる群より選択される1種又は2種以上の精油を含むことを特徴とする脂肪蓄積抑制用組成物である。
As a result of studies to solve the above problems, the present inventors have found that a specific essential oil has an effect of directly acting on adipose tissue and suppressing the accumulation of fat in fat cells, thereby completing the present invention. .
That is, the first subject of the present invention is eucalyptus oil, laurel oil, grapefruit oil, rosemary oil, clovebud oil, chamomile oil, rose oil, geranium oil, neroli oil, pine needle oil, hyssop oil, fennel oil, A fat accumulation-suppressing composition comprising one or more essential oils selected from the group consisting of clary sage oil and galvanum oil.
本発明の第二の主題は、前記組成物を含むことを特徴とする皮膚外用剤、痩身用化粧料、肥満改善剤、衣類、食品である。
本発明の第三の主題は、前記組成物を皮膚に塗布することを特徴とする脂肪蓄積抑制方法である。
The second subject of the present invention is an external preparation for skin, a slimming cosmetic, an obesity-improving agent, clothing and food, characterized by comprising the above composition.
The third subject of the present invention is a method for inhibiting fat accumulation, characterized in that the composition is applied to the skin.
本発明によれば、脂肪蓄積抑制効果の高い組成物を提供することが出来る。 According to the present invention, a composition having a high effect of suppressing fat accumulation can be provided.
以下、本発明の好適な実施形態について説明する。
本発明は、特定の精油が、脂肪組織に直接作用し、脂肪細胞内への脂肪の蓄積を抑制させる効果を有することに着目して行なわれたものであり、本発明にかかる脂肪蓄積抑制効果は、ユーカリオイル、ローレルオイル、グレープフルーツオイル、ローズマリーオイル、クローブバッドオイル、カモミールオイル、ローズオイル、ゼラニウムオイル、ネロリオイル、パインニードルオイル、ヒソップオイル、フェンネルオイル、クラリセージオイル、及びガルバナムオイルからなる群より選択される1種又は2種以上の精油を含むことにより発揮される。
Hereinafter, preferred embodiments of the present invention will be described.
The present invention was carried out paying attention to the fact that a specific essential oil has an effect of directly acting on adipose tissue and suppressing the accumulation of fat in fat cells, and the effect of inhibiting fat accumulation according to the present invention. Is a group consisting of Eucalyptus oil, Laurel oil, Grapefruit oil, Rosemary oil, Clovebud oil, Chamomile oil, Rose oil, Geranium oil, Neroli oil, Pine needle oil, Hyssop oil, Fennel oil, Clary sage oil, and Galvanum oil It is exhibited by including one or more essential oils selected more.
<ユーカリオイル>
フトモモ科に属する常緑喬木ユーカリの葉や小枝などを水蒸気蒸留することにより得られる精油である。
<ローレルオイル>
クスノキ科(Lauraceae)のゲッケイジュ属(Laurus)に属する常緑喬木ローレル(Laurus nobilis L.)の葉を乾燥後、水蒸気蒸留することにより得られる精油である。
<Eucalyptus oil>
It is an essential oil obtained by steam distillation of leaves, twigs, etc. of evergreen persimmon eucalyptus belonging to Myrtaceae.
<Laurel oil>
This is an essential oil obtained by steam distillation after drying leaves of Laurus nobilis L. belonging to the genus Laurus of the family Lauraceae.
<グレープフルーツオイル>
ミカン科の常緑樹グレープフルーツ(Citrus paradis Macf.)の果汁製造時にオイルを得る。
<ローズマリーオイル>
シソ科の常緑低木ローズマリー(Rosmarinus officinalis)の葉と花を水蒸気蒸留することにより得られる精油である。
<クローブバッドオイル>
フトモモ科クローブ(Eugenia caryophyllata)の開花前の花蕾を乾燥し、水蒸気蒸留することにより得られる精油である。
<Grapefruit oil>
Oil is obtained at the time of fruit juice production of Citrus paradis Macf.
<Rosemary oil>
It is an essential oil obtained by steam distillation of leaves and flowers of evergreen shrub Rosemary (Rosmarinus officinalis) of Lamiaceae.
<Clove Bad Oil>
It is an essential oil obtained by drying and steam-distilling flower buds before the flowering of Eugenia caryophyllata.
<カモミールオイル>
カモミール(Ormenis multicaulis)を水蒸気蒸留して得られる精油である。
<ローズオイル>
ダマスク・ローズ(Rosa damascena Mill.)、キャベジ・ローズ(Rosa centifolia L.)、ローザ・アルバ(Rosa alva L.)、ローザ・ガリカ( Rosa gallica L.)などのバラ科の花を水蒸気蒸留することにより得られる精油である。
<ゼラニウムオイル>
フウロウソウ科(Geraniaceae)のテンジクアオイPelargonium属の植物ニオイテンジクアオイP.graveolensの枝葉を開花前に収穫し、水蒸気蒸留することにより得られる精油である。
<Chamomile oil>
Chamomile the (Or m e n is mu l ticaul i s) is essential oil obtained by steam distillation.
<Rose oil>
Steam-distilling roses such as Damask Rose (Rosa damascena Mill.), Cabbage Rose (Rosa centifolia L.), Rosa alva L., Rosa gallica L. Is an essential oil.
<Geranium oil>
It is an essential oil obtained by harvesting the branches and leaves of the plant P. graveolens belonging to the genus Pelargonium belonging to the genus Pelargonium of the family Geraniaceae before flowering and steam distillation.
<ネロリオイル>
ミカン科のオレンジフラワー(Citrus aurantium subs pamera)の花を水蒸気蒸留することにより得られる精油である。
<パインニードルオイル>
マツ科のオウショウアカマツ(Pinus sylvestris)などのマツやモミ属(Abies)のトドマツなどの針葉、小枝を水蒸気蒸留することにより得られる精油である。
<ヒソップオイル>
シソ科ヤナギハッカ属のヒソップ(Hyssopus officinalis L.)の葉と花穂の部分を水蒸気蒸留することにより得られる精油である。
<Neroli Oil>
It is an essential oil obtained by steam distillation of the flowers of Citrus aurantium subs pamera.
<Pine needle oil>
It is an essential oil obtained by steam-distilling needles and twigs such as pine of Pinus sylvestris and Pinus sylvestris of the pine family and Abies.
<Hissop oil>
It is an essential oil obtained by steam-distilling the leaves and ears of Hyssopus officinalis L.
<フェンネルオイル>
セリ科の茴香または小茴香(Foeniculum vulgare Miller)の果実を水蒸気蒸留することにより得られる精油である。
<クラリセージオイル>
クラリセージ(Salvia sclarea L.)の開花期に、花穂または全草を水蒸気蒸留することにより得られる精油である。
<ガルバナムオイル>
セリ科のFerula galbanifuaおよび近縁植物の滲出物を精製することにより得られる精油である。
(以上、日本香料協会編「香りの百科」、朝倉書店編「最新 香料の事典」参照)
<Fennel oil>
It is an essential oil obtained by steam-distilling the fruits of the Aceraceae or Foeniculum vulgare Miller.
<Clary sage oil>
It is an essential oil obtained by steam-distilling flower spikes or whole plants during the flowering period of clary sage (Salvia sclarea L.).
<Galvanum oil>
It is an essential oil obtained by refining the exudates of Ferula galbanifua and related plants of the Apiaceae family.
(Please refer to “Encyclopedia of Scents” edited by Japan Fragrance Association, “Encyclopedia of Latest Fragrances” edited by Asakura Shoten)
なお、本発明の効果を損なわない範囲において、上記以外の精油を含むこともできる。
本発明にかかる脂肪蓄積抑制用組成物は、皮膚外用剤、食品、飼料、衣類、履物、アクセサリー等に応用することができる。
本発明の皮膚外用剤には上記した脂肪蓄積抑制用組成物の他に本発明の効果を損なわない範囲において、通常化粧品や、医薬部外品、医薬品等に用いられる他の成分、例えば、粉末成分、液体油脂、固体油脂、ロウ、炭化水素、高級脂肪酸、高級アルコール、エステル、シリコーン、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、非イオン界面活性剤、保湿剤、水溶性高分子、増粘剤、皮膜剤、紫外線吸収剤、金属イオン封鎖剤、低級アルコール、多価アルコール、糖、アミノ酸、有機アミン、高分子エマルジョン、pH調整剤、皮膚栄養剤、ビタミン、酸化防止剤、酸化防止助剤、香料、水等を必要に応じて適宜配合し、目的とする剤形に応じて常法により製造することが出来る。
In addition, in the range which does not impair the effect of this invention, essential oils other than the above can also be included.
The composition for suppressing fat accumulation according to the present invention can be applied to an external preparation for skin, food, feed, clothing, footwear, accessories and the like.
In the external preparation for skin of the present invention, in addition to the above-described composition for inhibiting fat accumulation, other ingredients usually used in cosmetics, quasi-drugs, pharmaceuticals, etc., as long as the effects of the present invention are not impaired, for example, powder Ingredients, liquid fats and oils, solid fats and oils, waxes, hydrocarbons, higher fatty acids, higher alcohols, esters, silicones, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, humectants, high water solubility Molecule, thickener, film agent, UV absorber, sequestering agent, lower alcohol, polyhydric alcohol, sugar, amino acid, organic amine, polymer emulsion, pH adjuster, skin nutrient, vitamin, antioxidant, Antioxidant auxiliaries, fragrances, water and the like can be appropriately blended as necessary, and can be produced by conventional methods according to the intended dosage form.
その他の配合可能成分としては、例えば、防腐剤(エチルパラベン、ブチルパラベン等);消炎剤(例えば、グリチルリチン酸誘導体、グリチルレチン酸誘導体、サリチル酸誘導体、ヒノキチオール、酸化亜鉛、アラントイン等);美白剤(例えば、胎盤抽出物、ユキノシタ抽出物、アルブチン等);各種抽出物(例えば、オウバク、オウレン、シコン、シャクヤク、センブリ、バーチ、セージ、ビワ、ニンジン、アロエ、ゼニアオイ、アイリス、ブドウ、ヨクイニン、ヘチマ、ユリ、サフラン、センキュウ、ショウキュウ、オトギリソウ、オノニス、ニンニク、トウガラシ、チンピ、トウキ、海藻等)、賦活剤(例えば、ローヤルゼリー、感光素、コレステロール誘導体等);血行促進剤(例えば、ノニル酸ワレニルアミド、ニコチン酸ベンジルエステル、ニコチン酸β−ブトキシエチルエステル、カプサイシン、ジンゲロン、カンタリスチンキ、イクタモール、タンニン酸、α−ボルネオール、ニコチン酸トコフェロール、イノシトールヘキサニコチネート、シクランデレート、シンナリジン、トラゾリン、アセチルコリン、ベラパミル、セファランチン、γ−オリザノール等);抗脂漏剤(例えば、硫黄、チアントール等);抗炎症剤(例えば、トラネキサム酸、チオタウリン、ヒポタウリン等)等が挙げられる。 Other ingredients that can be blended include, for example, preservatives (ethyl paraben, butyl paraben, etc.); anti-inflammatory agents (eg, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, etc.); Extract, placenta extract, saxifrage extract, arbutin, etc.); various extracts (eg, buckwheat, auren, shikon, peonies, assembly, birch, sage, loquat, carrot, aloe, mallow), iris, grape, yokuinin, loofah, lily , Saffron, nematode, ginger, hypericum, onionis, garlic, capsicum, chimney, red snapper, seaweed, etc.), activator (eg, royal jelly, photosensitizer, cholesterol derivative, etc.); blood circulation promoter (eg, nonyl acid wallenylamide, nicotine) Acid Gyl ester, nicotinic acid β-butoxyethyl ester, capsaicin, gingerone, cantalis tincture, ictamol, tannic acid, α-borneol, tocopherol nicotinate, inositol hexanicotinate, cyclandrate, cinnarizine, trazoline, acetylcholine, verapamil, cephalanthin , Γ-oryzanol, etc.); antiseborrheic agents (eg, sulfur, thianthol, etc.); anti-inflammatory agents (eg, tranexamic acid, thiotaurine, hypotaurine, etc.) and the like.
さらに、エデト酸二ナトリウム、エデト酸三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸、リンゴ酸等の金属封鎖剤、カフェイン、タンニン、ベラパミル、トラネキサム酸及びその誘導体、甘草、カリン、イチヤクソウ等の各種生薬抽出物、酢酸トコフェロール、グリチルレジン酸、グリチルリチン酸及びその誘導体又はその塩等の薬剤、ビタミンC、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド、アルブチン、コウジ酸等の美白剤、アルギニン、リジン等のアミノ酸及びその誘導体、フルクトース、マンノース、エリスリトール、トレハロース、キシリトール等の糖類等も適宜配合することができる。 Furthermore, edetate disodium, edetate trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, malic acid and other metal sequestering agents, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice, Various herbal extracts such as Karin and Ichiyakusou, drugs such as tocopherol acetate, glycyrrhizic acid, glycyrrhizic acid and derivatives or salts thereof, whitening agents such as vitamin C, magnesium ascorbate phosphate, glucoside ascorbate, arbutin, kojic acid, Amino acids such as arginine and lysine and derivatives thereof, saccharides such as fructose, mannose, erythritol, trehalose and xylitol can also be appropriately blended.
本発明の皮膚外用剤は、外皮に適用される化粧料、医薬品、及び医薬部外品に広く適用することが可能である。その剤型は任意であり、溶液系、可溶化系、乳化系、粉末分散系、水-油二層系、水-油-粉末三層系、ゲル、エアゾール、ミスト、及びカプセル等、任意の形態で提供されることができる。また、本発明の皮膚外用剤の製品形態も任意であり、マッサージ剤、フットスプレー等のボディー化粧料;浴用剤;化粧水、乳液、クリーム、パック等のフェーシャル化粧料;ファンデーション、おしろい、頬紅、口紅、アイシャドー、アイライナー、マスカラ、サンスクリーン等のメーキャップ化粧料;芳香化粧料;メーク落とし、洗顔料、ボディーシャンプー等の皮膚洗浄料;ヘアーリンス、シャンプー等の毛髪化粧料;軟膏;あぶら取り紙等、従来皮膚外用剤に用いるものであればいずれの形で適用することもできる。 The external preparation for skin of the present invention can be widely applied to cosmetics, pharmaceuticals, and quasi drugs applied to the outer skin. The dosage form is arbitrary, such as solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, gel, aerosol, mist, capsule, etc. It can be provided in the form. In addition, the product form of the external preparation for skin of the present invention is also arbitrary, body cosmetics such as massage agents and foot sprays; bath preparations; facial cosmetics such as lotions, emulsions, creams, packs, etc .; foundations, funny, blushers, Makeup cosmetics such as lipstick, eye shadow, eyeliner, mascara and sunscreen; aromatic cosmetics; skin cleansing agents such as make-up removers, facial cleansers, body shampoos; hair cosmetics such as hair rinses and shampoos; ointments; It can be applied in any form as long as it is used for conventional skin external preparations such as paper.
皮膚外用剤への上記精油の配合量は特に制限されないが、組成物全体の0.001〜50質量%、より好ましくは0.002〜30質量%であることが好ましい。0.001質量%未満であると十分な脂肪蓄積抑制効果が見られないことがあり、50質量%を超えて配合しても脂肪蓄積抑制効果のさらなる増加は見られにくい。
食品としては、パン、餅、麺類、乳製品、食用油脂、菓子、ジャム、蜂蜜、卵製品、飲料等に応用することができる。
衣類としては、肌着類、靴下、ストッキング、ガードル、ナイトウエア等に応用することができる。
The blending amount of the essential oil in the external preparation for skin is not particularly limited, but is preferably 0.001 to 50% by mass, more preferably 0.002 to 30% by mass based on the entire composition. If it is less than 0.001% by mass, a sufficient fat accumulation inhibitory effect may not be observed, and even if it exceeds 50% by mass, a further increase in fat accumulation inhibitory effect is hardly observed.
As food, it can be applied to bread, rice cakes, noodles, dairy products, edible fats and oils, confectionery, jam, honey, egg products, beverages and the like.
As clothing, it can be applied to underwear, socks, stockings, girdle, nightwear and the like.
以下、本発明の好適な実施例についてさらに詳しく説明する。なお、本発明はこれにより限定されるものではない。また、配合量(%)は特に記載のない限り質量%である。
脂肪蓄積抑制効果試験
本発明者らは、精油が脂肪蓄積を抑制する効果について検討を行なうため、ユーカリオイル、ローレルオイル、グレープフルーツオイル、ローズマリーオイル、クローブバッドオイル、カモミールオイル、ローズオイル、ゼラニウムオイル、ネロリオイル、パインニードルオイル、ヒソップオイル、フェンネルオイル、クラリセージオイル、及びガルバナムオイルの14種の精油を用い、以下の試験を行なった。
Hereinafter, preferred embodiments of the present invention will be described in more detail. In addition, this invention is not limited by this. Further, the blending amount (%) is mass% unless otherwise specified.
Fat accumulation inhibitory effect test The present inventors have studied eucalyptus oil, laurel oil, grapefruit oil, rosemary oil, clovebad oil, chamomile oil, rose oil, geranium oil in order to investigate the effect of essential oils to suppress fat accumulation. The following tests were carried out using 14 kinds of essential oils, neroli oil, pine needle oil, hyssop oil, fennel oil, clary sage oil, and galvanum oil.
<脂肪細胞の培養方法>
ラット皮下脂肪由来前駆脂肪細胞(東洋紡)を24ウェルプレートに2〜3×104個/ウェルの密度となる様に播種し、コンフルエントになるまで10%ウシ胎児血清を含むDMEM培地中で37℃、5%CO2の条件下で増殖培養を行なった。
コンフルエントに達した後、エタノールで希釈した各種精油を培地中での最終濃度が0.01%となる様に添加した分化培地に交換し、分化培養を行なった。分化培地には10μg/mlインシュリン、10μg/mlトランスフェリン、100μMデキサメタゾン、100μMインドメタシン、及び1%ウシ胎児血清を含むDMEM培地を用いた。対照として精油を分化培地に添加する際に希釈溶媒として用いたエタノール(培地中最終濃度0.01%)、陽性対照として既に脂肪細胞における脂肪蓄積抑制効果が報告されているカフェイン(培地中最終濃度200μg/ml)をそれぞれ分化培地に添加して培養を行ない、精油を添加した場合と比較した。
7日間分化培養後、生細胞数と細胞中に蓄積した中性脂肪量を測定して、各種精油の脂肪蓄積に対する効果を評価した。
<Adipocyte culture method>
Rat subcutaneous fat-derived preadipocytes (Toyobo) were seeded in 24-well plates at a density of 2-3 × 10 4 cells / well, and 37 ° C. in DMEM medium containing 10% fetal calf serum until confluent. Growth culture was performed under conditions of 5% CO 2 .
After reaching confluence, various essential oils diluted with ethanol were replaced with a differentiation medium added to a final concentration of 0.01% in the medium, and differentiation culture was performed. As the differentiation medium, DMEM medium containing 10 μg / ml insulin, 10 μg / ml transferrin, 100 μM dexamethasone, 100 μM indomethacin, and 1% fetal bovine serum was used. Ethanol used as a dilution solvent when adding essential oil to differentiation medium as a control (final concentration 0.01% in the medium), and caffeine as a positive control that has been reported to suppress fat accumulation in fat cells (final in medium) Culturing was carried out by adding 200 μg / ml) to the differentiation medium, and compared with the case where essential oil was added.
After differentiation culture for 7 days, the number of viable cells and the amount of neutral fat accumulated in the cells were measured to evaluate the effect of various essential oils on fat accumulation.
<生細胞数の測定方法>
7日間の分化培養終了後、各ウェルにトリプシンを添加し、細胞をはがす。トリパンブルーを添加して生細胞を染色し、顕微鏡下にて血球計算盤で生細胞数を計測した。
<Method for measuring the number of living cells>
After completion of differentiation culture for 7 days, trypsin is added to each well and the cells are detached. Trypan blue was added to stain viable cells, and the number of viable cells was counted with a hemocytometer under a microscope.
<中性脂肪量の定量方法>
生細胞数を測定後、各ウェルをPBS(0.5ml/ウェル)で2回づつ洗浄し、中性脂肪測定キット(リピドスリキッド 小野薬品株式会社製)を用いて脂肪細胞内に蓄積した中性脂肪量を測定した。
すなわち、細胞を溶解させ、グリセロールキナーゼで既存の遊離グリセロールを消去させた後、リポプロテインキナーゼを添加して中性脂肪(トリグリセライド)を分解させてグリセロールを生成させ、生成したグリセロールを、発色基質を用いた酵素反応法で定量することで、細胞中の中性脂肪量を定量した。検量線はトリオレインを用いて作製した。
<Method for determining the amount of neutral fat>
After measuring the number of viable cells, each well was washed twice with PBS (0.5 ml / well) and accumulated in fat cells using a neutral fat measurement kit (Lipidos Liquid Ono Pharmaceutical Co., Ltd.) Sex fat mass was measured.
That is, cells are lysed and existing free glycerol is erased with glycerol kinase, then lipoprotein kinase is added to decompose neutral fat (triglyceride) to produce glycerol, and the produced glycerol is used as a chromogenic substrate. The amount of triglycerides in the cells was quantified by quantifying with the enzyme reaction method used. A calibration curve was prepared using triolein.
<結果>
図1に各種精油を添加した場合の、生細胞数と、細胞当たりの中性脂肪量を、それぞれ対象の値を100とした場合の相対%で示した。
図1から明らかなように、ユーカリオイル、ローレルオイル、グレープフルーツオイル、ローズマリーオイル、クローブバッドオイル、カモミールオイル、ローズオイル、ゼラニウムオイル、ネロリオイル、パインニードルオイル、ヒソップオイル、フェンネルオイル、クラリセージオイル、及びガルバナムオイル添加の場合、顕著な脂肪蓄積抑制効果が確認された。また、従来脂肪蓄積抑制効果が知られているカフェインと比較しても、脂肪蓄積抑制効果がより高いことが確認された。
<Result>
In FIG. 1, the number of living cells and the amount of neutral fat per cell when various essential oils are added are shown as relative% when the target value is 100, respectively.
As is clear from Fig. 1, eucalyptus oil, laurel oil, grapefruit oil, rosemary oil, clove bud oil, chamomile oil, rose oil, geranium oil, neroli oil, pine needle oil, hyssop oil, fennel oil, clary sage oil, In addition, in the case of adding galvanum oil, a remarkable effect of suppressing fat accumulation was confirmed. Moreover, it was confirmed that the fat accumulation inhibitory effect is higher than caffeine, which has been known to have a fat accumulation inhibitory effect.
特にフェンネルオイル、ゼラニウムオイル、カモミールオイル、ローズマリーオイル、ヒソップオイル、クラリセージオイル、ローレルオイル、ガルバナムオイル、及びグレープフルーツオイルは、生細胞数の変化が小さく、細胞に対する影響が少ないため、脂肪蓄積抑制精油として望ましい効果を持っていると考えられる。
以下に、本発明を実施するために好適な処方例を挙げるが、本発明の技術範囲はこれら実施例により限定されるものではない。
In particular, fennel oil, geranium oil, chamomile oil, rosemary oil, hyssop oil, clary sage oil, laurel oil, galvanum oil, and grapefruit oil have a small change in the number of living cells and have little effect on cells. It is considered to have a desirable effect.
Examples of suitable formulations for carrying out the present invention are given below, but the technical scope of the present invention is not limited by these examples.
<処方例1 脂肪蓄積抑制用組成物>
(処方) (質量%)
1. レモンオイル 10
2. ベルガモットオイル 30
3. グレープフルーツオイル 10
4. ガルバナムオイル 0.2
5. リナロール 6
6. リナリルアセテート 8
7. フェンネルオイル 0.3
8. ゼラニウムオイル 1.5
9. ラベンダーオイル 2
10.シトロネロール 1
11.シトラール 0.5
12.ゲラニルアセテート 0.5
13.メチルイオノン 1
14.メチルジハイドロジャスモネート 10
15.パチョリオイル 1
16.ヘキシルシンナミックアルデヒド 2
17.ヘリオナール 1
18.クマリン 1
19.ベルトフィックス 2
20.クラリセージオイル 1
21.サンダルウッドオイル 1
22.エベルニル 0.5
23.ローズマリーオイル 1
24.オイゲノール 2
25.ジプロピレングリコール 6.5
<Prescription Example 1 Composition for inhibiting fat accumulation>
(Prescription) (mass%)
1. Lemon oil 10
2. Bergamot oil 30
3. Grapefruit oil 10
4). Galvanum oil 0.2
5. Linalool 6
6). Linalyl acetate 8
7). Fennel oil 0.3
8). Geranium oil 1.5
9. Lavender oil 2
10. Citronellol 1
11. Citral 0.5
12 Geranyl acetate 0.5
13. Methyl ionone 1
14 Methyl dihydrojasmonate 10
15. Patchouli oil 1
16. Hexylcinnamic aldehyde 2
17. Helionar 1
18. Coumarin 1
19. Belt fix 2
20. Clarisage oil 1
21. Sandalwood oil 1
22. Evernil 0.5
23. Rosemary oil 1
24. Eugenol 2
25. Dipropylene glycol 6.5
<処方例2 脂肪蓄積抑制用組成物>
(処方) (質量%)
1. レモンオイル 5
2. ベルガモットオイル 15
3. グレープフルーツオイル 3
4. リナロール 3
5. リナリルアセテート 5
6. ゼラニウムオイル 3
7. ラベンダーオイル 10
8. シトロネロール 1
9. メチルイオノン 1
10.メチルジハイドロジャスモネート 2
11.パチョリオイル 2
12.クマリン 1
13.ベチルベニルアセテート 2
14.クラリセージオイル 3
15.ヒソップオイル 1
16.ローレルオイル 0.5
17.カモミールオイル 1
18.ユーカリオイル 10
19.サンダルウッドオイル 4
20.エベルニル 0.5
21.ローズマリーオイル 5
22.オイゲノール 1
23.ジプロピレングリコール 2
24.ガラクソリド 50% 4
25.ベチルベンオイル 3
26.イソEスーパー 10
27.ベンジルアセテート 2
<Prescription Example 2 Composition for inhibiting fat accumulation>
(Prescription) (mass%)
1. Lemon oil 5
2. Bergamot oil 15
3. Grapefruit oil 3
4). Linalool 3
5. Linalyl acetate 5
6). Geranium oil 3
7). Lavender oil 10
8). Citronellol 1
9. Methyl ionone 1
10. Methyl dihydrojasmonate 2
11. Patchouli oil 2
12 Coumarin 1
13. Betylbenyl acetate 2
14 Clarisage oil 3
15. Hyssop oil 1
16. Laurel oil 0.5
17. Chamomile oil 1
18. Eucalyptus oil 10
19. Sandalwood oil 4
20. Evernil 0.5
21. Rosemary oil 5
22. Eugenol 1
23. Dipropylene glycol 2
24. Garaxolid 50% 4
25. Betilbene oil 3
26. Iso E Super 10
27. Benzyl acetate 2
<処方例3 化粧水>
(処方) (質量%)
1.グリセリン 2
2.ジプロピレングリコール 2
3.PEG−60 水添ひまし油 0.3
4.キシリトール 3
5.アスコルビン酸 0.005
6.EDTA3ナトリウム 0.1
7.染料 適量
8.本発明の脂肪蓄積抑制用組成物 適量
9.精製水 残量
10.カフェイン 0.1
<Prescription example 3 lotion>
(Prescription) (mass%)
1. Glycerin 2
2. Dipropylene glycol 2
3. PEG-60 hydrogenated castor oil 0.3
4). Xylitol 3
5. Ascorbic acid 0.005
6). EDTA3 sodium 0.1
7). Dye proper amount8. 8. Composition for inhibiting fat accumulation according to the present invention Purified water remaining amount 10. Caffeine 0.1
<処方例4 化粧水>
(処方) (質量%)
1.アルコール 30
2.ブチレングリコール 4
3.グリセリン 2
4.PPG−13デシルテトラデス24 0.3
5.オクチルメトキシシンナメート 0.1
6.メントール 0.2
7.トラネキサム酸 1.0
8.EDTA3ナトリウム 0.1
9.染料 適量
10.本発明の脂肪蓄積抑制用組成物 適量
11.精製水 残量
<Formulation example 4 lotion>
(Prescription) (mass%)
1. Alcohol 30
2. Butylene glycol 4
3. Glycerin 2
4). PPG-13 decyltetrades 24 0.3
5. Octyl methoxycinnamate 0.1
6). Menthol 0.2
7). Tranexamic acid 1.0
8). EDTA3 sodium 0.1
9. Dye proper amount
Ten. Composition for inhibiting fat accumulation of the present invention
11. Purified water remaining
<処方例5 乳液>
(処方) (質量%)
1.エチルアルコール 10
2.グリセリン 3
3.ブチレングリコール 2
4.ポリエチレングリコール 3
5.カルボキシビニルポリマー 0.1
6.アクリル酸/アクリル酸アルキルコポリマー 0.1
7.苛性カリ 0.1
8.シクロメチコン 4
9.スクワラン 2
10.球状ポリエチレン 2
11.メントール 0.5
12.コラデカバロ 0.3
13.パラベン 適量
14.EDTA3ナトリウム 0.1
15.顔料 適量
16.本発明の脂肪蓄積抑制用組成物 適量
17.精製水 残量
<Formulation Example 5 Latex>
(Prescription) (mass%)
1. Ethyl alcohol 10
2. Glycerin 3
3. Butylene glycol 2
4). Polyethylene glycol 3
5. Carboxyvinyl polymer 0.1
6). Acrylic acid / alkyl acrylate copolymer 0.1
7). Caustic potash 0.1
8). Cyclomethicone 4
9. Squalane 2
Ten. Spherical polyethylene 2
11. Menthol 0.5
12. Corade Cavallo 0.3
13. Paraben appropriate amount
14. EDTA3 sodium 0.1
15. Pigment appropriate amount
16. Composition for inhibiting fat accumulation of the present invention
17. Purified water remaining
<処方例6 乳液>
(処方) (質量%)
1.ブチレングリコール 4
2.プロピレングリコール 4
3.カルボキシビニルポリマー 0.2
4.苛性カリ 0.2
5.ベヘニン酸 0.5
6.ステアリン酸 0.5
7.イソステアリン酸 0.5
8.ステアリン酸グリセリル 1
9.イソステアリン酸グリセリル 1
10.ベヘニルアルコール 0.5
11.バチルアルコール 0.5
12.スクワラン 5
13.トリオクタノイン 3
14.フェニルトリメチコン 2
15.ブナの芽エキス 0.5
16.フェノキシエタノール 適量
17.EDTA3ナトリウム 0.1
18.顔料 適量
19.本発明の脂肪蓄積抑制用組成物 適量
20.精製水 残量
21.カフェイン 0.3
<Formulation Example 6 Latex>
(Prescription) (mass%)
1. Butylene glycol 4
2. Propylene glycol 4
3. Carboxyvinyl polymer 0.2
4). Caustic potash 0.2
5. Behenic acid 0.5
6). Stearic acid 0.5
7). Isostearic acid 0.5
8). Glyceryl stearate 1
9. Glyceryl isostearate 1
Ten. Behenyl alcohol 0.5
11. Batyl alcohol 0.5
12. Squalane 5
13. Trioctanoin 3
14. Phenyltrimethicone 2
15. Beech bud extract 0.5
16. Appropriate amount of phenoxyethanol
17. EDTA3 sodium 0.1
18. Pigment appropriate amount
19. Composition for inhibiting fat accumulation of the present invention
20. Purified water remaining
twenty one. Caffeine 0.3
<処方例7 乳液>
(処方) (質量%)
1.グリセリン 3
2.キシリトール 2
3.カルボキシビニルポリマー 0.1
4.苛性カリ 0.1
5.イソステアリン酸グリセリル 1
6.ステアリン酸グリセリル 0.5
7.ベヘニルアルコール 1
8.バチルアルコール 1
9.パーム硬化油 2
10.ワセリン 1
11.スクワラン 5
12.オクタン酸エリスリチル 3
13.シクロメチコン 1
14.アスコルビン酸リン酸エステルマグネシウム 0.5
15.パラベン 適量
16.EDTA3ナトリウム 0.1
17.本発明の脂肪蓄積抑制用組成物 残量
18.精製水 残量
<Prescription Example 7 Latex>
(Prescription) (mass%)
1. Glycerin 3
2. Xylitol 2
3. Carboxyvinyl polymer 0.1
4). Caustic potash 0.1
5. Glyceryl isostearate 1
6). Glyceryl stearate 0.5
7). Behenyl alcohol 1
8). Batyl alcohol 1
9. Palm hardened oil 2
Ten. Vaseline 1
11. Squalane 5
12. Erythrityl octoate 3
13. Cyclomethicone 1
14. Ascorbic acid phosphate magnesium 0.5
15. Paraben appropriate amount
16. EDTA3 sodium 0.1
17. Composition for inhibiting fat accumulation of the present invention
18. Purified water remaining
<処方例8 クリーム>
(処方) (質量%)
1.グリセリン 10
2.ブチレングリコール 5
3.カルボキシビニルポリマー 0.1
4.苛性カリ 0.2
5.ステアリン酸 2
6.ステアリン酸グリセリル 2
7.イソステアリン酸グリセリル 2
8.ワセリン 5
9.ステアリルアルコール 2
10.ベヘニルアルコール 2
11.パーム硬化油 2
12.スクワラン 10
13.αグルコシルヘスペリジン 0.1
14.パラベン 適量
15.EDTA3ナトリウム 0.1
16.顔料 適量
17.本発明の脂肪蓄積抑制用組成物 適量
18.精製水 残量
19.カフェイン 0.5
<Prescription Example 8 Cream>
(Prescription) (mass%)
1. Glycerin 10
2. Butylene glycol 5
3. Carboxyvinyl polymer 0.1
4). Caustic potash 0.2
5. Stearic acid 2
6). Glyceryl stearate 2
7). Glyceryl isostearate 2
8). Vaseline 5
9. Stearyl alcohol 2
Ten. Behenyl alcohol 2
11. Palm hardened oil 2
12. Squalane 10
13. α-Glucosyl hesperidin 0.1
14. Paraben appropriate amount
15. EDTA3 sodium 0.1
16. Pigment appropriate amount
17. Composition for inhibiting fat accumulation of the present invention
18. Purified water remaining
19. Caffeine 0.5
<処方例9 クリーム>
(処方) (質量%)
1.グリセリン 3
2.ジプロピレングリコール 7
3.ポリエチレングリコール 3
4.ステアリン酸グリセリル 3
5.イソステアリン酸グリセリル 2
6.ステアリルアルコール 2
7.ベヘニルアルコール 2
8.流動パラフィン 7
9.シクロメチコン 3
10.ジメチコン 1
11.オクチルメトキシシンナメート 0.1
12.ビタミンAアセテート 0.5
13.フェノキシエタノール 適量
14.EDTA3ナトリウム 0.1
15.顔料 適量
16.本発明の脂肪蓄積抑制用組成物 適量
17.精製水 残量
<Prescription Example 9 Cream>
(Prescription) (mass%)
1. Glycerin 3
2. Dipropylene glycol 7
3. Polyethylene glycol 3
4). Glyceryl stearate 3
5. Glyceryl isostearate 2
6). Stearyl alcohol 2
7). Behenyl alcohol 2
8). Liquid paraffin 7
9. Cyclomethicone 3
Ten. Dimethicone 1
11. Octyl methoxycinnamate 0.1
12. Vitamin A acetate 0.5
13. Appropriate amount of phenoxyethanol
14. EDTA3 sodium 0.1
15. Pigment appropriate amount
16. Composition for inhibiting fat accumulation of the present invention
17. Purified water remaining
<処方例10 ジェル>
(処方) (質量%)
1.エチルアルコール 10
2.グリセリン 5
3.ブチレングリコール 5
4.カルボキシビニルポリマー 0.5
5.AMP 0.3
6.PEG−60水添ひまし油 0.3
7.メントール 0.02
8.油溶性甘草エキス(根) 0.2
9.パラベン 適量
10.EDTA3ナトリウム 0.1
11.本発明の脂肪蓄積抑制用組成物 適量
12.精製水 残量
<Prescription Example 10 Gel>
(Prescription) (mass%)
1. Ethyl alcohol 10
2. Glycerin 5
3. Butylene glycol 5
4). Carboxyvinyl polymer 0.5
5. AMP 0.3
6). PEG-60 hydrogenated castor oil 0.3
7). Menthol 0.02
8). Oil-soluble licorice extract (root) 0.2
9. Paraben appropriate amount
Ten. EDTA3 sodium 0.1
11. Composition for inhibiting fat accumulation of the present invention
12. Purified water remaining
<処方例11 エアゾール>
(処方) (質量%)
1.グリセリン 2
2.ジプロピレングリコール 2
3.PEG−60水添ひまし油 0.3
4.コラデカバロ(根葉) 0.5
5.パラベン 適量
6.EDTA3ナトリウム 0.1
7.染料 適量
8.本発明の脂肪蓄積抑制用組成物 適量
9.精製水 残量
10.窒素ガス 0.8
11.カフェイン 0.1
<Prescription Example 11 Aerosol>
(Prescription) (mass%)
1. Glycerin 2
2. Dipropylene glycol 2
3. PEG-60 hydrogenated castor oil 0.3
4). Corade cavalo (root leaves) 0.5
5. Paraben appropriate amount 6. EDTA3 sodium 0.1
7). Dye proper amount8. 8. Composition for inhibiting fat accumulation according to the present invention Purified water remaining
Ten. Nitrogen gas 0.8
11. Caffeine 0.1
<処方例12 エアゾール>
(処方) (質量%)
1.アルコール 15
2.ブチレングリコール 2
3.グリセリン 1
4.PPG−13 デシルテトラデス24 0.1
5.4−メトキシサリチル酸カリウム 0.5
6.EDTA3ナトリウム 0.1
7.染料 適量
8.本発明の脂肪蓄積抑制用組成物 適量
9.精製水 残量
10.LPG 40
<Prescription Example 12 Aerosol>
(Prescription) (mass%)
1. Alcohol 15
2. Butylene glycol 2
3. Glycerin 1
4). PPG-13 Decyltetrades 24 0.1
5.4 Potassium 4-methoxysalicylate 0.5
6). EDTA3 sodium 0.1
7). Dye proper amount8. 8. Composition for inhibiting fat accumulation according to the present invention Purified water remaining
Ten. LPG 40
<処方例13 入浴剤>
(処方) (質量%)
1.硫酸ナトリウム 45.0
2.炭酸水素ナトリウム 45.0
3.ヒソップオイル 10.0
4.本発明の脂肪蓄積抑制用組成物 適量
<Prescription Example 13 Bath Agent>
(Prescription) (mass%)
1. Sodium sulfate 45.0
2. Sodium bicarbonate 45.0
3. Hyssop oil 10.0
4). Composition for inhibiting fat accumulation of the present invention
<処方例14 フォームパック>
(処方) (質量%)
1.カフェイン 1.0
2.メタリン酸ナトリウム 0.02
3.トレハロース 2.0
4.グリセリン 7.0
5.メチルパラベン 0.1
6.水酸化カリウム 0.15
7.ステアリン酸 0.5
8.ミリスチン酸 1.0
9.バチルアルコール 1.5
10.ポリオキシエチレン(60)硬化ヒマシ油 3.0
11.フェンネルオイル 0.3
12.液化石油ガス 6.0
13.ジメチルエーテル 3.0
14.本発明の脂肪蓄積抑制用組成物 適量
15.精製水 残余
<Formulation Example 14 Foam Pack>
(Prescription) (mass%)
1. Caffeine 1.0
2. Sodium metaphosphate 0.02
3. Trehalose 2.0
4). Glycerin 7.0
5. Methylparaben 0.1
6). Potassium hydroxide 0.15
7). Stearic acid 0.5
8). Myristic acid 1.0
9. Batyl alcohol 1.5
Ten. Polyoxyethylene (60) hydrogenated castor oil 3.0
11. Fennel oil 0.3
12. Liquefied petroleum gas 6.0
13. Dimethyl ether 3.0
14. Composition for inhibiting fat accumulation of the present invention
15. Purified water residue
<処方例15 シャンプー>
(処方) (質量%)
1.ラウリルポリエキシエチレン(3)硫酸エステルナトリウム塩 10.0
2.ラウリル硫酸エステルナトリウム塩 5.0
3.ヤシ油脂肪酸ジエタノールアミド 4.0
4.グリセリン 1.0
5.本発明の脂肪蓄積抑制用組成物 適量
6.色素 適量
7.パラベン 適量
8.EDTA3ナトリウム 0.1
9.クエン酸 0.05
10.クエン酸ナトリウム 0.05
11.精製水 残余
<Prescription Example 15 Shampoo>
(Prescription) (mass%)
1. Lauryl polyethylene (3) sulfate sodium salt 10.0
2. Lauryl sulfate sodium salt 5.0
3. Palm oil fatty acid diethanolamide 4.0
4). Glycerin 1.0
5. 5. Composition for inhibiting fat accumulation according to the present invention Appropriate amount of dye 7. Paraben appropriate amount 8. EDTA3 sodium 0.1
9. Citric acid 0.05
Ten. Sodium citrate 0.05
11. Purified water residue
<処方例16 シャンプー>
(処方) (質量%)
1.ラウリルポリエキシエチレン(3)硫酸エステルトリエタノールアミン塩
5.0
2.ラウリルポリエキシエチレン(3)硫酸エステルナトリウム塩
5.0
3.ラウリル硫酸エステルナトリウム塩 5.0
4.ラウロイルモノエタノールアミド 1.0
5.ラウリルジメチルアミノ酢酸ベタイン 5.0
6.カチオン化セルロース 7.0
7.エチレングリコールジステアリン酸エステル 2.0
8.タンパク質誘導体 0.5
9.本発明の脂肪蓄積抑制用組成物 適量
10.EDTA3ナトリウム 0.1
11.クエン酸 0.05
12.クエン酸ナトリウム 0.05
13.精製水 残余
14.カフェイン 0.3
<Prescription Example 16 Shampoo>
(Prescription) (mass%)
1. Lauryl polyethylene (3) sulfate triethanolamine salt
5.0
2. Lauryl polyethylene (3) sulfate sodium salt
5.0
3. Lauryl sulfate sodium salt 5.0
4). Lauroyl monoethanolamide 1.0
5. Lauryldimethylaminoacetic acid betaine 5.0
6). Cationized cellulose 7.0
7). Ethylene glycol distearate 2.0
8). Protein derivative 0.5
9. Composition for inhibiting fat accumulation of the present invention
Ten. EDTA3 sodium 0.1
11. Citric acid 0.05
12. Sodium citrate 0.05
13. Purified water residue
14. Caffeine 0.3
<処方例17 リンス>
(処方) (質量%)
1.シリコーン油 3.0
2.流動パラフィン 1.0
3.セチルアルコール 1.5
4.ステアリルアルコール 1.0
5.塩化ステアリルトリメチルアンモニウム 0.7
6.グリセリン 3.0
7.本発明の脂肪蓄積抑制用組成物 適量
8.色素 適量
9.フェノキシエタノール 適量
10.精製水 残余
<Prescription Example 17 Rinse>
(Prescription) (mass%)
1. Silicone oil 3.0
2. Liquid paraffin 1.0
3. Cetyl alcohol 1.5
4). Stearyl alcohol 1.0
5. Stearyltrimethylammonium chloride 0.7
6). Glycerin 3.0
7). 7. An appropriate amount of the composition for inhibiting fat accumulation according to the present invention 8. Appropriate amount of dye Appropriate amount of phenoxyethanol
Ten. Purified water residue
<処方例18 繊維>
キュプロアンモニウムセルロース溶液(セルロース濃度10質量%、アンモニウム濃度7質量%、銅濃度3.6質量%、)に、本発明の精油を内包したマイクロカプセル(粒経50μm以下、マイクロカプセルに占める精油の割合は50質量%)をセルロース質量に対して0.1〜20質量%の範囲内で添加、混和したのち、通常の湿式防糸方法にしたがって紡糸し、精練工程、乾燥工程を経て繊維を得た。
<Prescription Example 18 Fiber>
Microcapsules containing cupro ammonium cellulose solution (cellulose concentration 10% by mass, ammonium concentration 7% by mass, copper concentration 3.6% by mass) containing the essential oil of the present invention (
<処方例19 アイスクリーム>
(質量%)
1.脱脂粉乳 8.8
2.砂糖 5.5
3.マルトース水あめ 15.6
4.エリスリトール 4.4
5.ヒマワリ油 11.7
6.パーム油 1.3
7.乳化安定剤(サンソフトスーパー250:太陽化学(株)製) 0.3
8.水 52.0
9.本発明の脂肪蓄積抑制用組成物 0.2
10.バニラ香料(昭和農芸(株)製) 0.2
(製法)
1〜8を均一に混合溶解し、65℃に加温して2段階(150kg/cm2及び50kg/cm2)で均質化し、85℃で15秒間殺菌し、5℃以下に急冷した。9、10を添加し、均一に混合した後、タンク中で一夜エージングを行った。このミックスを連続式フリーザーでオーバーラン30%でフリージングし、温度−7.0〜−8.0℃で冷菓用の紙カップに充填し、−35℃の冷凍庫で急速凍結した。
<Prescription Example 19 Ice Cream>
(mass%)
1. Nonfat dry milk 8.8
2. 5.5 sugar
3. Maltose Mizuame 15.6
4). Erythritol 4.4
5. Sunflower oil 11.7
6). Palm oil 1.3
7). Emulsification stabilizer (Sunsoft Super 250: manufactured by Taiyo Chemical Co., Ltd.) 0.3
8). Water 52.0
9. Composition for inhibiting fat accumulation of the present invention 0.2
10. Vanilla flavor (made by Showa Agricultural Co., Ltd.) 0.2
(Manufacturing method)
1 to 8 were mixed and dissolved uniformly, heated to 65 ° C., homogenized in two stages (150 kg / cm 2 and 50 kg / cm 2 ), sterilized at 85 ° C. for 15 seconds, and rapidly cooled to 5 ° C. or lower. After adding 9, 10 and mixing uniformly, aging was performed overnight in the tank. This mix was frozen with a continuous freezer at an overrun of 30%, filled into a paper cup for frozen dessert at a temperature of -7.0 to -8.0 ° C, and quickly frozen in a freezer at -35 ° C.
<処方例20 ドライドッグフード>
トウモロコシ30部、小麦粉30部、脱脂大豆15部、ミートミール10部、チキンミール5部、ビタミンミネラルミックス1部、及び本発明の脂肪蓄積抑制用組成物1部からなる組成物を混合、粉砕し、1mmの開口を有する篩を用いて整粒した。得られた組成物に約27質量%となるように加水し、クッキングエクストルーダーに8mmの円型ダイスを装着し押出し処理を行ない、膨化物を得た。得られた膨化物をベルト式乾燥機により120℃、20分で乾燥した後、膨化物95部に対してダイズ油を5部噴霧してドライドッグフードを得た。
<Prescription Example 20 Dry Dog Food>
Mix and grind a composition comprising 30 parts of corn, 30 parts of wheat flour, 15 parts of defatted soybean, 10 parts of meat meal, 5 parts of chicken meal, 1 part of vitamin mineral mix, and 1 part of the composition for inhibiting fat accumulation of the present invention. The size was adjusted using a sieve having an opening of 1 mm. Water was added to the obtained composition so as to be about 27% by mass, an 8 mm circular die was attached to the cooking extruder, and extrusion treatment was performed to obtain an expanded product. The obtained expanded product was dried at 120 ° C. for 20 minutes by a belt dryer, and then 5 parts of soybean oil was sprayed on 95 parts of the expanded product to obtain a dry dog food.
Claims (4)
An obesity-improving agent comprising one or two essential oils selected from the group consisting of neroli oil and pine needle oil.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003433948A JP4691320B2 (en) | 2003-12-26 | 2003-12-26 | Composition for inhibiting fat accumulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003433948A JP4691320B2 (en) | 2003-12-26 | 2003-12-26 | Composition for inhibiting fat accumulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005187432A JP2005187432A (en) | 2005-07-14 |
JP4691320B2 true JP4691320B2 (en) | 2011-06-01 |
Family
ID=34791173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003433948A Expired - Lifetime JP4691320B2 (en) | 2003-12-26 | 2003-12-26 | Composition for inhibiting fat accumulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4691320B2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2007026645A1 (en) * | 2005-08-31 | 2009-03-05 | ネイチャーテクノロジー株式会社 | Dietary composition containing plant essential oil component as active ingredient, dietary sheet composition containing the composition, pharmaceutical preparation for percutaneous absorption type diet, and production method thereof |
JP2007302572A (en) * | 2006-05-09 | 2007-11-22 | Pokka Corp | Brain function improver and brain function-improving composition containing the same |
JP2009254296A (en) * | 2008-04-17 | 2009-11-05 | Sofia Ecoplan:Kk | Liquid seasoning and method for producing the same |
FR2972926B1 (en) * | 2011-03-21 | 2013-11-29 | Oreal | COSMETIC COMPOSITION COMPRISING FENNEL ESSENTIAL OIL AND NONIONIC SURFACTANT. |
ITRM20110484A1 (en) * | 2011-09-14 | 2013-03-15 | Francesca Festa | COSMETIC METHOD AND COSMETIC FORMULATIONS FOR USE IN THE SAME METHOD. |
CN103669013A (en) * | 2012-09-19 | 2014-03-26 | 江苏澳丹奴家纺有限公司 | Production method of detachable sleep-assistant quilt head |
JP2014065682A (en) * | 2012-09-26 | 2014-04-17 | Shiseido Co Ltd | Expression modulator for clock gene period |
JP2014224073A (en) * | 2013-05-16 | 2014-12-04 | 地方独立行政法人北海道立総合研究機構 | Elastase activity inhibitor comprising leaf extracts of pinaceae abies plant |
JP6538421B2 (en) * | 2015-05-20 | 2019-07-03 | エステー株式会社 | Bath agent |
WO2017027591A1 (en) * | 2015-08-10 | 2017-02-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for treating obesity |
CN106691904A (en) * | 2015-08-24 | 2017-05-24 | 无限极(中国)有限公司 | Composition, preparation method and use thereof, skincare product containing composition, and preparation method of skincare product |
CN107596066A (en) * | 2017-08-30 | 2018-01-19 | 云南宏绿辣素有限公司 | A kind of Weight reducing essential oil |
JP6572337B2 (en) * | 2018-02-28 | 2019-09-04 | 株式会社ファンケル | Composition for promoting myokine production |
CN109833265A (en) * | 2019-03-29 | 2019-06-04 | 李春燕 | A kind of essential oil of moulding weight reducing |
TWI816109B (en) * | 2021-04-22 | 2023-09-21 | 佐登妮絲國際股份有限公司 | Composition of essential oil with fat-reducing effect |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0427389A (en) * | 1990-05-21 | 1992-01-30 | Nippon Flour Mills Co Ltd | Amylase inhibitor |
JPH07316064A (en) * | 1993-11-10 | 1995-12-05 | Morishita Jintan Kk | Suppressor for causative of periodontal disease or caries and composition for oral cavity and food containing the same |
JPH09209265A (en) * | 1996-01-26 | 1997-08-12 | Lion Corp | Spray type sizing agent composition |
JPH09241127A (en) * | 1996-03-04 | 1997-09-16 | Nonogawa Shoji Kk | Body reducing agent composition for cosmetic |
JP2001270833A (en) * | 2000-01-18 | 2001-10-02 | Nagaoka Koryo Kk | Antiobesity agent |
JP2002179586A (en) * | 2000-12-15 | 2002-06-26 | Fancl Corp | Lipase inhibitor |
JP2002265977A (en) * | 2000-12-25 | 2002-09-18 | Shiseido Co Ltd | Perfume composition capable of activating sympathetic nerve |
WO2003010381A1 (en) * | 2001-07-26 | 2003-02-06 | Symrise Gmbh & Co. Kg | Fragrance compositions for co2 dry cleaning process |
JP2003192585A (en) * | 2001-12-27 | 2003-07-09 | Lion Corp | Oral composition |
JP2003206225A (en) * | 2002-01-11 | 2003-07-22 | Ichimaru Pharcos Co Ltd | Cosmetic composition and beauty and healt food composition |
JP2004075640A (en) * | 2002-08-22 | 2004-03-11 | Fancl Corp | Agent for inhibiting differentiation of lipocyte |
JP2004161624A (en) * | 2002-11-11 | 2004-06-10 | Noevir Co Ltd | Aqueous sticklike slimming cosmetic |
JP2004250804A (en) * | 2003-02-18 | 2004-09-09 | Teijin Fibers Ltd | Sympathetic nerve-activating fabric |
JP2005053891A (en) * | 2003-07-18 | 2005-03-03 | Seresu Corporation:Kk | Lipase inhibitor |
-
2003
- 2003-12-26 JP JP2003433948A patent/JP4691320B2/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0427389A (en) * | 1990-05-21 | 1992-01-30 | Nippon Flour Mills Co Ltd | Amylase inhibitor |
JPH07316064A (en) * | 1993-11-10 | 1995-12-05 | Morishita Jintan Kk | Suppressor for causative of periodontal disease or caries and composition for oral cavity and food containing the same |
JPH09209265A (en) * | 1996-01-26 | 1997-08-12 | Lion Corp | Spray type sizing agent composition |
JPH09241127A (en) * | 1996-03-04 | 1997-09-16 | Nonogawa Shoji Kk | Body reducing agent composition for cosmetic |
JP2001270833A (en) * | 2000-01-18 | 2001-10-02 | Nagaoka Koryo Kk | Antiobesity agent |
JP2002179586A (en) * | 2000-12-15 | 2002-06-26 | Fancl Corp | Lipase inhibitor |
JP2002265977A (en) * | 2000-12-25 | 2002-09-18 | Shiseido Co Ltd | Perfume composition capable of activating sympathetic nerve |
WO2003010381A1 (en) * | 2001-07-26 | 2003-02-06 | Symrise Gmbh & Co. Kg | Fragrance compositions for co2 dry cleaning process |
JP2003192585A (en) * | 2001-12-27 | 2003-07-09 | Lion Corp | Oral composition |
JP2003206225A (en) * | 2002-01-11 | 2003-07-22 | Ichimaru Pharcos Co Ltd | Cosmetic composition and beauty and healt food composition |
JP2004075640A (en) * | 2002-08-22 | 2004-03-11 | Fancl Corp | Agent for inhibiting differentiation of lipocyte |
JP2004161624A (en) * | 2002-11-11 | 2004-06-10 | Noevir Co Ltd | Aqueous sticklike slimming cosmetic |
JP2004250804A (en) * | 2003-02-18 | 2004-09-09 | Teijin Fibers Ltd | Sympathetic nerve-activating fabric |
JP2005053891A (en) * | 2003-07-18 | 2005-03-03 | Seresu Corporation:Kk | Lipase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
JP2005187432A (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3258942B1 (en) | Cosmetic and topical compositions comprising cannabigerol and cannabidiol | |
CN104000752B (en) | Ginger extract for stem cell protection | |
TWI433680B (en) | New cosmetic and/or pharmaceutical compositions and their applications | |
JP4691320B2 (en) | Composition for inhibiting fat accumulation | |
JPWO2004016236A1 (en) | Cosmetics | |
CN102387838A (en) | Cosmetic compositions comprising polyhydroxyltate fatty alcohols and derivatives and uses thereof | |
JP2001288066A (en) | Skin barrier function ameliorator | |
JP2020511514A (en) | Composition for promoting melanin production containing thistle extract as an active ingredient | |
CN107530273A (en) | Composition containing Valerian root P.E | |
KR100708236B1 (en) | Cosmetic composition comprising the flower extract of Camellia japonica L. showing astringent activity | |
WO2013012197A2 (en) | Composition for preventing or alleviating skin wrinkles containing honeybush extract or a fermented liquor thereof as an active ingredient | |
WO2012014901A1 (en) | Carbonylation inhibitor | |
KR100776755B1 (en) | Composition comprising crude drug extract showing anti-itching effect | |
KR20190048564A (en) | Cosmetic composition comprising concentrate of Omegiju fermented using magma seawater for improving wrinkles, elasticity or moisturizing the skin | |
JP2008184441A (en) | External preparation for skin for promoting fibroblast proliferation | |
JP2005194252A (en) | Fat accumulation-suppressing composition | |
KR20200104999A (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR100564107B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
JP2010222273A (en) | Hair-growing agent composition | |
JP2005187431A (en) | Fat accumulation promoting composition | |
KR20190021114A (en) | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract | |
JP6249516B2 (en) | Transglutaminase activator | |
JP2005029556A (en) | Skin aging-preventing agent | |
KR20160043698A (en) | Composition for treating hair or scalp to prevent hair loss | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110201 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4691320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |